Report on Antihypertensive Drug Market

Product Code SFC00114
Publication Date May 2009
Publisher Sunfaith China
Product Type Report
Pages 15
ISBN Number not applicable

Report on Antihypertensive Drug Market

It is learned that China's hypertension morbidity rate of adults is 18.8%, treatment rate is 6.1%, and it also takes on a lowering trend of age, which attracting more and more people's attention on hypertension. Thus there is a greater demand for antihypertensive drug, and China's market scale of antihypertensive drug is still very huge in the future. This report carries out specific analysis and research of three major antihypertensive drug types, i.e.classification of current hypertension, and drug market competition. It points out that although there is a huge market demand of antihypertensive drug, the competition is still fierce.

Contents

  • 1 Introduction of hypertension
    • 1.1 Classification
    • 1.2 Types of antihypertensive drug
  • 2 Market analysis of antihypertensive drug
    • 2.1 Market scale
    • 2.2 Subdivison of market share
    • 2.3 Market competition
  • 3 CCB hypotensor
    • 3.1 Amlodipine
    • 3.2 Nifedipine
    • 3.3 Felodipine
  • 4 ARB hypotensor
    • 4.1 Valsartan
    • 4.2 Losartan Potassium
    • 4.3 Irbesartan
  • 5 beta-blocker hypotensor
    • 5.1 Potassium magnessium aspartape
    • 5.2 Metoprolol
  • 6 Analysis of antihypertensive drug market demand
    • 6.1 China's rising morbidity rate of hypertension
    • 6.2 Low hypertension treatment rate and control rate
    • 6.3 Huge market demand for antihypertensive drug
  • 7 Conclusion